News and Announcements
Additional Placement Raises $1.0 million for Prescient Therapeutics
- Published November 26, 2015 11:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
24th November 2015, ASX Announcement
Cancer drug development company Prescient Therapeutics Limited (ASX: PTX) (‘Prescient’, ‘PTX’ or ‘the Company’) advises that following the oversubscribed Share Purchase Plan (‘SPP’), the Company has subsequently raised approximately $1.0million. The Company is completing an additional top up placement of approximately 19.3 million fully paid ordinary shares at $0.054 (5.4 cents) per share, which is the same price as the SPP issue price. Together with the recently completed SPP, PTX has raised approximately $2.0 million, exceeding the Company’s expectations.
PTX expects these funds to provide for efforts to achieve multiple milestones across its clinical programs over the next 12 to 18 months.
To read the full announcement, please click here.